Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and weight loss compared to GLP-1 receptor analogues (semaglutide, dulaglutide) in patients with type 2 diabetes.
For patients with Type 2 Diabetes seeking significant weight loss and glucose control, tirzepatide offers superior efficacy compared to existing GLP-1 analogues like semaglutide. It is administered as a once-weekly injection, starting at 5mg and titrating up to 15mg, combined with diet and exercise.
StrongSupportsVERY_HIGH confidence
current studies show that the glucose lowering and weight loss effects of tirzepatide are at least as effective as GLP-1 RAs with a similar adverse effect profile. Some studies, though not conclusive, predict that tirzepatide may in fact be more potent than GLP-1 RAs at reducing weight.
Why this rating
Based on multiple Phase III randomized controlled trials (SURPASS series) with large sample sizes and statistically significant results.
Source
Beyond glycemia: Comparing tirzepatide to GLP-1 analogues
John Andraos et al. · Reviews in Endocrine and Metabolic Disorders · 2023
narrative_reviewCited 45×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →